KRX300, KOSDAQ stocks are biotyped

KRX300, KOSDAQ stocks are biotyped

Korea Exchange, Announcement of added items Kospi 237, KOSDAQ 68

Celltrion 3 brothers, Silla Zen, and so on.

Celltrion 3 and Sirajen will be included in the KRX 300, the KOSPI integrated index, which will be released next month. KOSDAQ stocks of 'KRX 300' are mainly made up of biotech stocks.

According to the Korea Exchange, the KRX 300 index will include 305 stocks, including 237 total KOSPI stocks and 68 KOSDAQ stocks.

KRX 300 constituents are regularly changed twice a year in June and December every year, and the constituent stocks announced this time are selected as the regular change criteria in December last year. Although 300 stocks are the criteria, 5 stocks have been added as 5 stocks in the index have been re-listed after the split. It is scheduled to be revised to 300 items in June.

In terms of the total market capitalization of the constituent stocks, 92.7% is in the KOSPI market and 44.7% in the KOSDAQ market. The market capitalization of KRX 300 is 84.7%.

About KRX 300 In the market, interest in KOSDAQ stocks is high.

The KOSDAQ market share in the KRX 300 index is 8.9%. This is more than the 6.5% of the KOSDAQ market capitalization announced by the Korea Exchange.

The increase is attributable to the possibility that Celltrion, the No. 1 player in the KOSDAQ market, will be listed on the KOSPI market during the next month.

Of the KRX 300 constituents, Celltrion accounted for 2.7% of the total, and the KOSDAQ portion of the KOSDAQ will decrease from 8.9% to 6.2%.

However, there are still some disappointments among KOSDAQ companies.

If we look at the number of stocks, the portion of KOSDAQ in the KRX 300 is 22.2%. Most of them, however, contain the same phenomenon as the celltrion 3 brothers, Shinragen and Meditox.

A KOSDAQ company official said, "Although the new integration index is positive, most companies in the KOSDAQ will not be able to do so."

Meanwhile, KRX 300 selected KRX 300 as the market size and liquidity criterion among the stocks that are practically able to manage funds among the common stocks listed on the KOSPI and KOSDAQ market.